In vivo studies have shown that some experimental compounds and drugs currently used clinically can activate PP2 A and consequently reverse AD-like tau phosphorylation and associated cognitive impairment, for instance, sodium selenate, by increasing PP2 A activity through unknown mechanisms. This evidence concerns the gene MAPT and Alzheimer disease.